IonOpticks, a global provider of high-performance chromatography columns for proteomics research, has expanded its UK presence by taking laboratory and office space at 127 Olympic Avenue, Milton Park, Oxfordshire.
The new facility will serve as IonOpticks’ local European headquarters and applications laboratory, bringing stock, technical support, applications expertise and method development closer to customers across the UK and Europe.
About IonOpticks
Headquartered in Melbourne, Australia and founded in 2017 by scientists, IonOpticks develops advanced chromatography columns that enable researchers around the world to analyse proteins with greater speed, sensitivity and reproducibility. Its technology is helping accelerate research into disease mechanisms, biomarker and drug discovery, and the development of more targeted medicines across cancer, neurological disorders and other complex diseases.
Closer to customers, closer to science
With local personnel available in the same time zones as the researchers they support, the new Milton Park facility will enable faster delivery, more responsive collaboration and closer engagement with customers, research institutions and partners. This reflects IonOpticks’ commitment to being a strategic research and workflow partner, rather than simply a supplier of consumables.
Milton Park’s life sciences community includes global biotechnology companies such as Immunocore, Vertex Pharmaceuticals and New England Biolabs, alongside innovative businesses including NeoVac and Verso Biosense. It benefits from close links to the University of Oxford, Harwell Campus and the wider Oxford-Cambridge Growth Corridor.
Xavier Perronnet, CEO of IonOpticks, said: “Milton Park gives IonOpticks the ideal environment from which to deepen our support for customers across the UK and Europe. Its strong scientific community and proximity to leading research institutions align closely with our ambition to provide not only faster access to our products, but also local expertise, applications support and collaborative method development.
“As demand for our technology continues to grow internationally, establishing our first overseas office at Milton Park has provided an excellent platform for the next phase of our expansion. Having recently moved in, we already have a growing number of UK-based employees on site, so choosing Milton Park has already proven to be the right decision.
“We are excited to be part of the Milton Park community and look forward to working alongside other innovative organisations that are advancing scientific discovery and improving human health.”
Clare Fleet, asset manager of Milton Park at Federated Hermes Real Estate, said: “IonOpticks is a brilliant addition to Milton Park’s life sciences community. The company’s work is enabling researchers around the world to advance proteomics and improve our understanding of disease, making a real contribution to future healthcare innovation.”
A community built for science and innovation
Milton Park is one of the UK’s largest single ownership innovation communities, home to more than 280 organisations across science, technology and business. Through its flexible accommodation, collaborative community and reliable infrastructure, the Park supports organisations from ambitious start-ups through to established international businesses as they innovate, grow and scale. Signal Yard, its new social and retail destination, further strengthens the offer for the thousands of people who live and work across the estate.
Photo credit: IonOpticks
